drugset

drugset / Trial / NCT00193687

Bifeprunox in the Treatment of Schizophrenia

NCT00193687 ↗

Phase 3 Completed 986 enrolled Solvay Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia. Extension to study S154.3.001.

Timeline

Start: 2005-09
Primary completion: 2008-01
Completion: 2008-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bifeprunox	Small molecule	—	—

Indications